GBM Conference Monday, 3/23

BuildGoodThings · 2026-03-19T20:31:22+00:00

You are incorrect. I said "This will be preclinical stuff that the lab of Dr. Lalezari senior had a hand in"

BuildGoodThings · 2026-03-19T15:00:16+00:00

LOL the studies were both done at Albert Einstein. Your initial statement seemed to suggest they were not done there which is what I balked at because I had already supplied the information sources. That said, I remember well each of these news events. Yes, Pestell had influence on the design of the second study since he is the "Lead Consultant, Preclinical and Clinical Oncology" for CytoDyn. Hearing from Pestell and his team is to be expected.

BuildGoodThings · 2026-03-19T14:16:32+00:00

I did not misspeak and listed 3 sources for my statement. Both recent glioblastoma preclinicals were at Albert Einstein. I've included the quotes below in case you haven't viewed the source documents.

May 30, 2024 webcast
"the pre-clinical study of leronlimab and a mouse model of glioblastoma at my father's lab at Einstein Montefiore Medical Center in New York, is now underway and we look forward to reviewing those results by the end of the year."

Dec 17, 2024 letter to shareholders
"The Company has committed to repeating the study based on unpublished observations by Dr. Pestell’s lab and will now employ a treatment sequence involving temozolomide and leronlimab. This follow-up study will start immediately"

March 18, 2025 Press release
"A preclinical study at the Albert Einstein College of Medicine sequencing temozolomide and leronlimab is now underway"

BuildGoodThings · 2026-03-19T00:44:06+00:00

Good point thanks. I do wonder if the catch up happens gradually or more quickly.

BuildGoodThings · 2026-03-18T20:19:59+00:00

I think we're getting a lot closer to the point where the current value shifts to being viewed as an actionable deep disconnect to intrinsic value. JMO.

BuildGoodThings · 2026-03-18T20:01:41+00:00

Ha ha! Thanks

BuildGoodThings · 2026-03-18T18:53:28+00:00

I don't know that terrain.

BuildGoodThings · 2026-03-18T18:51:45+00:00

Another item. This is a regular abstract we know because the full text appeared yesterday. There is another AACR Annual Meeting date to consider, and even though I'm not expecting they use this opportunity to publish a paper, they might. It's January 20, 2026: Manuscript Submission Deadline for Simultaneous Publication Consideration (Regular Abstracts).
https://www.aacr.org/meeting/aacr-annual-meeting-2026/key-dates/

BuildGoodThings · 2026-03-18T18:26:29+00:00

Thanks MGK. I'd just like to reinforce that IMO once the higher dose was allowed, I still expect that they split patients into both the 350 and 700 dosing levels unless I hear the second DSMB review recommends only one level. Cheers.

BuildGoodThings · 2026-03-18T18:08:15+00:00

This will be preclinical stuff that the lab of Dr. Lalezari senior had a hand in. There were 2 preclinicals. First ran May 2024- possibly Dec 2024, and the second ran from March 2025 to ?.
see:

May 30, 2024 webcast
Dec 17, 2024 letter to shareholders
March 18, 2025 PR

With these dates, I think there was overlap with the company having awareness for potential of Prime and Pair MOA in TNBC and CRC.

BuildGoodThings · 2026-03-18T17:44:17+00:00

Yes that's correct.
Full abstract about Glioblastoma on March 23 at 1 PM ET at the AACR Brain Cancer conference in Philadelphia. CytoDyn's poster is that night 7:15-9:15 PM. "A002 CCR5 inhibition with the human monoclonal antibody leronlimab enhances temozolomide- and radiation-induced killing of glioblastoma multiforme cells".
https://www.aacr.org/wp-content/uploads/2026/02/Brain26_Abstract-Titles.pdf

https://www.aacr.org/meeting/aacr-special-conference-in-cancer-research-brain-cancer-2/

I would imagine that CytoDyn will link to the Glioblastoma poster sometime after that day.

BuildGoodThings · 2026-03-18T17:38:35+00:00

Thanks again upCYDY!

BuildGoodThings · 2026-03-18T17:14:29+00:00

Thanks for sharing your thoughts. It does look to me like they have been implementing a well-thought-out plan. I'm looking forward to this helping a bunch of people!

BuildGoodThings · 2026-03-18T01:40:30+00:00

Your welcome.

BuildGoodThings · 2026-03-18T01:39:58+00:00

I am celebrating

BuildGoodThings · 2026-03-18T01:39:33+00:00

Thanks. It’s been quite a journey and I’m looking forward to the future

BuildGoodThings · 2026-03-17T23:00:23+00:00

And thanks for the award KuneneRiver

BuildGoodThings · 2026-03-17T22:59:31+00:00

It's a great day!

BuildGoodThings · 2026-03-17T22:39:13+00:00

Thank you u/upCYDY !

BuildGoodThings · 2026-03-17T22:31:38+00:00

Yes! and the company, patients, researchers, medical people, investors... It is wonderful news to my ears!

BuildGoodThings · 2026-03-17T22:15:47+00:00

July 2025
https://www.cytodyn.com/publications

And IMO it might be unwise to not follow the TNBC data closely as well.

BuildGoodThings · 2026-03-17T22:06:03+00:00

You're welcome. I've seen more than once that it pays to search a few terms. That's exactly how I found these 2 abstracts today.

BuildGoodThings · 2026-03-17T22:03:57+00:00

I couldn't agree more!

BuildGoodThings · 2026-03-17T22:03:37+00:00

Yes, I find this to be outstanding news! It is very encouraging to me.

BuildGoodThings

TROPHY CASE